natgillin/translations-raw huggingface dataset:
Given that low dose ritonavir (100 mg twice daily) has been shown to have no significant effect on methadone concentrations, no interaction is expected if methadone is co- administered with atazanavir, based on these data.
Budući da se pokazalo da niska doza ritonavira (100 mg dvaput na dan) nema značajan učinak na koncentraciju metadona, na temelju tih se podataka ne očekuje interakcija kod istovremene primjene metadona i atazanavira.
PDE5 inhibitors used for the treatment of erectile dysfunction: particular caution should be used when prescribing PDE5-inhibitors (sildenafil, tadalafil, or vardenafil) for the treatment of erectile dysfunction in patients receiving Atazanavir Krka.
Inhibitori PDE5 koji se primjenjuju za liječenje erektilne disfunkcije: potreban je poseban oprez kad se propisuju inhibitori PDE5 (sildenafil, tadalafil ili vardenafil) za liječenje erektilne disfunkcije u bolesnika koji primaju Atazanavir Krka.
Based on data obtained with other boosted PIs and ketoconazole, where ketoconazole AUC showed a 3-fold increase, atazanavir /ritonavir is expected to increase ketoconazole or itraconazole concentrations.
Na temelju podataka dobivenih s drugim pojačanim inhibitorima proteaze i ketokonazola, gdje je AUC ketokonazola pokazivao trostruko povećanje, očekuje se da će atazanvir s ritonavirom povećati koncentraciju ketokonazola ili itrakonazola.
The content of the capsule is yellowishwhite to yellow-white powder.
Sadržaj kapsule je žućkastobijeli do žutobijeli prašak.
Your doctor may adjust the dose of Atazanavir Krka according to your anti-HIV therapy.
Liječnik će možda prilagoditi dozu lijeka Atazanavir Krka prema Vašoj anti-HIV terapiji.
G73, V82, I84, and L90 (0-2, 3, 4 or more) at baseline.
A71, G73, V82, I84 i L90 (0-2, 3, 4 ili više) na početku.
During attempts to overcome the decreased exposure by increasing the dose of atazanavir or other protease inhibitors with ritonavir, a high frequency of liver reactions was seen.
Tijekom pokušaja da se prevlada smanjena izloženost povećanjem doze atazanvira ili drugih inhibitora proteaze s ritonavirom, opažena je velika učestalost jetrenih reakcija.
Antiviral activity in vitro: atazanavir exhibits anti-HIV-1 (including all clades tested) and anti-HIV-2 activity in cell culture.
Antivirusno djelovanje in vitro: atazanavir u staničnoj kulturi ima anti-HIV-1 (uključujući sve ispitane skupine) i anti-HIV-2 djelovanje.
Number of patients with paired genotypes classified as virological failures (HIV RNA ≥ 400 copies/ml).
Broj bolesnika s uparenim genotipovima klasificiranih kao virološki neuspjeh (HIV RNA ≥ 400 kopija/ml).
A dose reduction of the glucocorticoid should be considered with close monitoring of local and systemic effects or a switch to a glucocorticoid, which is not a substrate for CYP3A4 (e.g., beclomethasone).
Potrebno je razmotriti sniženje doze glukokortikoida uz pažljivo praćenje lokalnih i sistemskih učinaka ili prebacivanje na glukokortikoid koji nije supstrat enzima CYP3A4 (npr.,
If the patient has developed SJS or DRESS associated with the use of Atazanavir Krka, Atazanavir Krka may not be restarted.
Ako je bolesnik razvio SJS ili DRESS povezan s primjenom lijeka Atazanavir Krka, Atazanavir Krka se možda neće ponovno uvesti u terapiju.
See section 2 "Atazanavir Krka contains lactose monohydrate".
Vidjeti dio 2. "Atazanavir Krka sadrži laktozu hidrat".
Protease inhibitors: The co-administration of atazanavir /ritonavir and other protease inhibitors has not been studied but would be expected to increase exposure to other protease inhibitors.
Inhibitori proteaze: Istovremena primjena atazanvira s ritonavirom i drugih inhibitora proteaze nije ispitana, ali pretpostavlja se da bi povećala izloženost drugim inhibitorima proteaze.
Co-administration of alfuzosin concentrations which can result in hypotension.
Postoji mogućnost povišenih koncentracija alfuzosina koje mogu dovesti do hipotenzije.
In clinical studies AI424-397 and AI424-451, paediatric patients 3 months to less than 11 years of age had a mean duration of treatment with atazanavir oral powder of 80 weeks.
U kliničkim ispitivanjima AI424-397 i AI424-451 u pedijatrijskih bolesnika u dobi od 3 mjeseca do manje od 11 godina, srednje trajanje liječenja atazanavir oralnim praškom iznosilo je 80 tjedana.
Children receiving Atazanavir Krka may require their heart to be monitored.
Kod djece koja uzimaju Atazanavir Krka možda će biti potrebno pratiti rad srca.
300 mg hard capsules:
300 mg tvrde kapsule:
- During this time, postpartum patients should follow the same dose recommendation as for non- pregnant patients, including those for co-administration of medicinal products known to affect atazanavir exposure (see section 4.5).
- Tijekom ovog vremena, bolesnice u postpartalnom razdoblju trebaju nastaviti s istom dozom kakva se preporučuje bolesnicama koje nisu trudne, uključujući one koje istovremeno primaju lijekove za koje se zna da utječu na izloženost atazanaviru (vidjeti dio 4.5).
Each hard capsule contains 79.43 mg lactose monohydrate.
Jedna tvrda kapsula sadrži 79,43 mg laktoza hidrata.
Patients should not breast-feed while taking Atazanavir Krka.
Bolesnice ne smiju dojiti dok uzimaju Atazanavir Krka.
If an oral contraceptive is administered with atazanavir/ritonavir, it is recommended that the oral contraceptive contain at least 30 μg of ethinyloestradiol and that the patient be reminded of strict compliance with this contraceptive dosing regimen.
Ako se oralna kontracepcija primjenjuje s atazanvirom s ritonavirom preporučje se da oralna kontracepcija sadrži najmanje 30 μg etinilestradiola i da se bolesnici istakne važnost redovitog uzimanja kontracepcije kod ovog kontracepcijskog režima.
30 hard capsules
30 tvrdih kapsula
Renal impairment: in healthy subjects, the renal elimination of unchanged atazanavir was approximately 7% of the administered dose.
Posebne populacije Oštećenje funkcije bubrega: U zdravih je ispitanika eliminacija neizmijenjenog atazanavira putem bubrega iznosila približno 7% primijenjene doze.
In clinical trial AI424-182 atazanavir /ritonavir (300/100 mg or 400/100 mg) in combination with zidovudine/lamivudine was administered to 41 pregnant women during the second or third trimester.
U kliničkom je ispitivanju AI424-182 atazanavir/ritonavir (300/100 mg ili 400/100 mg) u kombinaciji sa zidovudinom/lamivudinom bio primijenjen u 41 trudnice tijekom drugog ili trećeg tromjesečja.
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occurs many months after initiation of treatment.
Pojava autoimunih poremećaja (poput Gravesove bolesti i autoimunog hepatitisa) također je bila prijavljena prilikom imunološke reaktivacije; međutim, prijavljeno vrijeme do nastanka je jako varijabilno te ovi događaji mogu nastati puno mjeseci nakon početka liječenja.
Atazanavir concentrations were greatly decreased when coadministered with didanosine (buffered tablets) and stavudine.
Koncentracije atazanavira jako su se smanjile kad je primijenjen istovremeno s didanozinom (puferirane tablete) i stavudinom.
Age/Gender: a study of the pharmacokinetics of atazanavir was performed in 59 healthy male and female subjects (29 young, 30 elderly).
Dob/Spol: Ispitivanje farmakokinetike atazanavira provedeno je u 59 zdravih muškaraca i žena
Co-administration with a high-fat meal did not affect the AUC of atazanavir relative to fasting conditions and the cmax was within 11% of fasting values.
Istovremena primjena s obrokom bogatim mastima nije utjecala na AUC atazanavira u odnosu na stanje natašte i Cmax je bio unutar 11%
Efficacy data observed in the 41 paediatric patients aged 6 years to less than 18 years that received atazanavir capsules with ritonavir are presented in Table 7.
Podaci o djelotvornosti opaženoj u 41 pedijatrijskog bolesnika u dobi od 6 godina do manje od 18 godina koji su primali atazanavir kapsule s ritonavirom prikazani su u tablici 7.
Atazanavir should not be used in combination with medicinal products that are substrates of CYP3A4 and have a narrow therapeutic index.
Atazanvir se ne smije primjenjivati u kombinaciji s lijekovima koji su supstrati enzima CYP3A4 i imaju uzak terapijski indeks.
If you notice any symptoms of infection, please inform your doctor immediately.
Ako primijetite ikakve simptome infekcije, odmah o tome obavijestite svog liječnika.
If atazanavir is co-administered with irinotecan, patients should be closely monitored for adverse events related to irinotecan.
Ako se atazanvir primjenjuje istovremeno s irinotekanom, bolesnike treba pažljivo pratiti zbog nuspojava povezanih s irinotekanom.
When given with atazanavir, the recommended dose of rifabutin is 150 mg 3 times per week on set days (for example MondayWednesday-Friday).
preporučena doza rifabutina je 150 mg tri puta tjedno u određene dane (na primjer, ponedjeljak srijeda-petak).
Cmin ng/mLb
Cmax ng/mL
The mechanism of interaction between atazanavir/ritonavir and sofosbuvir/velpatasvir/voxilaprevir is inhibition of OATP1B, Pgp, and CYP3A.
Mehanizam interakcije između atazanavir/ritonavir i sofosbuvir/velpatasvir/voksilaprevir je inhibicija OATP1B, Pgp, i CYP3A.
Some medicines may interact with ritonavir, a medicine that is taken with Atazanavir Krka.
Neki lijekovi mogu ući u interakciju s ritonavirom, koji se uzima zajedno s lijekom Atazanavir Krka.
What you need to know before you take Atazanavir Krka
Što morate znati prije nego počnete uzimati Atazanavir Krka
LIPID LOWERING AGENTS HMG-CoA reductase inhibitors Simvastatin Lovastatin
Inhibitori reduktaze HMG-CoA Simvastatin
Metabolism and nutrition disorders uncommon: weight decreased, weight gain, anorexia, appetite increased
Poremećaji metabolizma i prehrane: manje često: smanjenje tjelesne težine, povećanje tjelesne težine, anoreksija, pojačan apetit
FC susceptibility in cell culture relative to the wild-type reference was assayed using PhenoSenseTM (Monogram Biosciences, South San Francisco, California, USA)
FC osjetljivosti u staničnoj kulturi u odnosu na referentni divlji tip ispitala se pomoću PhenoSenseTM (Monogram
Administration of atazanavir with ritonavir with either a light or a high-fat meal decreased the coefficient of variation of AUC and cmax by approximately 25% compared to the fasting state.
Primjena atazanavira s ritonavirom uz lagani obrok ili obrok bogat mastima smanjila je koeficijent varijacije AUC i Cmax za približno 25% u usporedbi s onima natašte.
Capsule contents: lactose monohydrate, crospovidone (type A) and magnesium stearate.
Sadržaj kapsule: laktoza hidrat, krospovidon (vrste A) i magnezijev stearat.
A large prospective observational study has shown an association between an increased incidence of chronic kidney disease and cumulative exposure to atazanavir/ritonavir-containing regimen in HIV-infected patients with an initially normal eGFR.
Veliko prospektivno opservacijsko ispitivanje pokazalo je povezanost između povećane incidencije kronične bubrežne bolesti i kumulativnog izlaganja režimu koji sadrži atazanavir/ritonavir u bolesnika zaraženih HIV-om, s početno normalnom eGFR.
Food effect: co-administration of atazanavir and ritonavir with food optimises the bioavailability of atazanavir.
Utjecaj hrane: Istovremena primjena atazanavira i ritonavira s hranom optimizira bioraspoloživost atazanavira.
In a clinical study AI424-020, paediatric patients 3 months to less than 18 years of age who received either the oral powder or capsule formulation had a mean duration of treatment with atazanavir of 115 weeks.
U kliničkom ispitivanju AI424-020 u pedijatrijskih bolesnika u dobi od 3 mjeseca do manje od 18 godina koji su primali ili formulaciju oralnog praška ili formulaciju kapsule, srednje trajanje liječenja atazanavirom iznosilo je 115 tjedana.
The increase in progestin exposure may lead to related side-effects (e.g. insulin resistance, dyslipidemia, acne and spotting), thus possibly affecting the compliance.
Povećana izloženost progestinu može dovesti do s time povezanih nuspojava (npr., inzulinske rezistencije, dislipidemije, akni i probojnog krvarenja) i tako utjecati na uzimanje kontracepcije.
Reduced plasma concentrations of atazanavir may be the consequence of increased gastric pH if antacids, including buffered medicinal products, are administered with atazanavir.
Snižene koncentracije atazanavira u plazmi mogu biti posljedica povišenog želučanog pH ako se antacidi, uključujući puferirane lijekove, primjenjuju s atazanvirom.
- Yellowing of your skin or the white part of your eyes caused by high levels of bilirrubin in your blood has been commonly reported.
- Često je prijavljeno žutilo kože ili bjeloočnica koje je uzrokovano povišenim razinama bilirubina u Vašoj krvi.
Based on available virological and clinical data from adult patients, no benefit is expected in patients with strains resistant to multiple protease inhibitors (≥ 4 PI mutations).
Na temelju dostupnih viroloških i kliničkih podataka u odraslih bolesnika, ne očekuje se da će liječenje biti korisno u bolesnika zaraženih sojevima koji su rezistentni na više inhibitora proteaze
LIST OF EXCIPIENTS Contains also lactose monohydrate.
POPIS POMOĆNIH TVARI Sadrži također laktozu hidrat.
atazanavir (without ritonavir) has been studied in adult patients with severe renal impairment (n=20), including those on haemodialysis, at multiple doses of 400 mg once daily.
Atazanavir (bez ritonavira) ispitan je u odraslih bolesnika s teškim oštećenjem funkcije bubrega (n=20), uključujući one na hemodijalizi, pomoću višestrukih doza od 400 mg jedanput na dan.
bSee description of selected adverse reactions for more details.
Vidjeti opis odabranih nuspojava, za dodatne informacije.
If a higher dose of an H2-receptor antagonist is required (e.g., famotidine 40 mg twice daily or equivalent) an increase of the atazanavir /ritonavir dose from 300/100 mg to 400/100 mg can be considered.
Ako je potrebna viša doza antagonista H2 receptora (npr., famotidin 40 mg dvaput na dan ili ekvivalent) može se razmotriti povišenje doze atazanvira s ritonavirom s 300/100 mg na 400/100 mg.
The safety and efficacy of atazanavir has not been established in patients with significant underlying liver disorders.
Sigurnost i djelotvornost lijeka atazanavira nije ustanovljena u bolesnika sa značajnom osnovnom bolešću jetre.
Each hard capsule contains 158.86 mg lactose monohydrate.
Jedna tvrda kapsula sadrži 158,86 mg laktoza hidrata.
Efficacy Outcomes at Week 48a and at Week 96 (Study 045)
Tablica 6: Ishodi djelotvornsoti u 48. tjednua i 96. tjednu (Ispitivanje 045) Parameter
In paediatric patients with pre-existing conduction problems (second degree or higher atrioventricular or complex bundle-branch block), Atazanavir Krka should be used with caution and only if the benefits exceed the risk.
U pedijatrijskih bolesnika s već prisutnim poremećajem provođenja (atrioventrikularni blok drugog ili višeg stupnja ili kompletni blok grane) Atazanavir Krka treba primjenjivati s oprezom i samo ako je korist veća od rizika.
Do not take Atazanavir Krka: - if you are allergic to atazanavir or any of the other ingredients of this medicine (listed in section 6).
Nemojte uzimati Atazanavir Krka: - ako ste alergični na atazanavir ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.) - ako imate umjerene do teške tegobe s jetrom.
The pharmacokinetic data from HIV-infected pregnant women receiving atazanavir capsules with ritonavir are presented in Table 8.
Trudnoća: Farmakokinetički podaci prikupljeni u trudnica zaraženih HIV-om koje su uzimale atazanavir kapsule s ritonavirom prikazani su u tablici 8.
Although not studied, there is a potential for an increase in pravastatin or fluvastatin exposure when co- administered with protease inhibitors.
Iako interakcija nije ispitivana, postoji mogućnost povećane izloženosti pravastatinu ili fluvastatinu kada se primjenjuju zajedno s inhibitorima proteaze.
Atazanavir Krka 300 mg hard capsules are available in containers containing 30 hard capsules or 90 (3 x 30) hard capsules; in a box.
Atazanavir Krka 300 mg tvrde kapsule su dostupne u spremnicima koji sadrže 30 tvrdih kapsula ili 90 (3 x 30) tvrdih kapsula; u kutiji.
Co-administration of atazanavir with ritonavir at doses greater than 100 mg once daily has not been clinically evaluated.
Istovremena primjena lijeka atazanavira s ritonavirom u dozama višima od 100 mg jedanput na dan nije klinički procijenjena.
Systemic lidocaine, Quinidine
Amiodaron, Sistemski lidokain, Kinidin
When atazanavir/ritonavir is coadministered with either phenytoin or phenobarbital, a dose adjustment of phenytoin or phenobarbital may be required.
Kada se atazanvir s ritonavirom primjenjuje istodobno s fenitoinom ili fenobarbitalom, možda će biti potrebna prilagodba doze fenitoina ili fenobarbitala.
Atazanavir (without ritonavir) has been studied in adult subjects with moderate-to-severe hepatic impairment (14 Child-Pugh Class B and 2 Child-Pugh Class C subjects) after a single 400 mg dose.
Atazanavir (bez ritonavira) ispitivao se u odraslih ispitanika s umjerenim do teškim oštećenjem funkcije jetre (14 ispitanika s Child-Pugh stadijem B i 2 ispitanika s Child-Pugh stadijem C) nakon primjene jednokratne doze od 400 mg.
If the use of atorvastatin is considered strictly necessary, the lowest possible dose of atorvastatin should be administered with careful safety monitoring (see section 4.4).
treba primijeniti najnižu moguću dozu atorvastatina uz poman nadzor sigurnosti primjene (vidjeti dio 4.4).
The atazanavir /ritonavir arm showed similar (non-inferior) antiviral efficacy compared to the lopinavir/ritonavir arm, as assessed by the proportion of patients with HIV RNA < 50 copies/ml at week 48 (Table 5).
U skupini koja je primala atazanavir/ritonavir utvrđena je antivirusna djelotvornost slična (neinferiorna) onoj u skupini koja je primala lopinavir/ritonavir, što je procijenjeno na temelju udjela bolesnika s HIV RNK < 50 kopija/ml u 48. tjednu (tablica 5).
There is no specific antidote for overdose with Atazanavir Krka.
Ne postoji posebni antidot za predoziranje lijekom Atazanavir Krka.
In case of withdrawal of ritonavir from the initial recommended ritonavir boosted regimen (see section 4.4), unboosted Atazanavir Krka could be maintained in patients with mild hepatic impairment at a dose of 400 mg, and in patients with moderate hepatic impairment with a reduced dose of 300 mg once daily with food (see section 5.2).
U slučaju izostavljanja ritonavira iz početnog preporučenog režima pojačanog ritonavirom (vidjeti dio 4.4), nepojačani Atazanavir Krka može se nastaviti primjenjivati u bolesnika s blagim oštećenjem funkcije jetre u dozi od 400 mg, a u bolesnika s umjerenim oštećenjem funkcije jetre doza se mora smanjiti na 300 mg jedanput na dan i uzimati s hranom (vidjeti dio 5.2).
At the time voriconazole treatment is required, a patient's CYP2C19 genotype should be performed if feasible.
U trenutku kada je potrebno liječenje vorikonazolom treba, ako je to moguće, odrediti CYP2C19
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.8).
Redovito praćenje bubrežnih funkcija u bolesnika treba se održavati tijekom cijelog trajanja liječenja (vidjeti dio 4.8).
There are other medicines that may not mix with Atazanavir Krka.
Postoje i drugi lijekovi koji se ne smiju miješati s lijekom Atazanavir Krka.
When compared to atazanavir 300 mg with ritonavir 100 mg without tenofovir disoproxil, atazanavir concentrations are expected to be additionally decreased by about
300 mg s ritonavirom 100 mg bez tenofovirdizoproksila, očekuje se da će koncentracije atazanavira biti dodatno smanjene za približno 20%.
If the combination is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; doses of proton pump inhibitors comparable to omeprazole 20 mg should not be exceeded (see section 4.4).
Ako se prosudi da je ta kombinacija neizbježna, preporučuje se pažljiv klinički nadzor u kombinaciji s povišenjem doze atazanvira na 400 mg sa 100 mg ritonavira; ne smiju se prekoračiti doze inhibitora protonske pumpe usporedive s dozom omeprazola od 20 mg (vidjeti dio 4.4).
Regular monitoring of the renal function of patients should be maintained throughout the treatment duration (see section 4.4).
Redovito praćenje bubrežnih funkcija u bolesnika treba se održavati tijekom cijelog trajanja liječenja (vidjeti dio 4.4).
None of the de novo substitutions (see Table 4) are specific to atazanavir and may reflect reemergence of archived resistance on atazanavir + ritonavir in Study 045 treatment-experienced population.
Niti jedna od de novo supstitucija (vidjeti tablicu 4) nije specifična za atazanavir i može odražavati ponovnu pojavu stare rezistencije na atazanavir s ritonavirom u prethodno liječene populacije u
Atazanavir Krka given without ritonavir should not be used in pregnant patients given that it could result of suboptimal exposure of particular concern for the mother infection and vertical transmission.
Krka se bez ritonavira ne smije primjenjivati u trudnica jer to može dovesti do suboptimalne izloženosti lijeku, što je osobito problematično s obzirom na majčinu infekciju i vertikalni prijenos.
Co-administration with atazanavir with ritonavir warrants clinical monitoring for sedation and cognitive effects.
Istovremena primjena s atazanvirom i ritonavirom zahtijeva kliničko praćenje zbog sedacije i kognitivnih učinaka.
The most frequently reported laboratory abnormality in patients receiving regimens containing atazanavir and one or more NRTIs was elevated total bilirubin reported predominantly as elevated indirect [unconjugated] bilirubin (87% Grade 1, 2, 3, or 4).
Poremećaji laboratorijskih nalaza Najčešće zabilježeni laboratorijski nalaz u bolesnika koji primaju terapiju atazanavirom i jednim ili više NRTI-jeva bio je povišen ukupni bilirubin zabilježen pretežno kao povišeni indirektni [nekonjugirani] bilirubin (87% 1., 2., 3. ili 4. stupnja).
Co-administration of atazanavir /ritonavir with other hormonal contraceptives or oral contraceptives containing progestogens other than norgestimate has not been studied, and therefore should be avoided.
Istovremena primjena atazanvira s ritonavirom i druge hormonske ili oralne kontracepcije koja sadrži progestagene, osim norgestimata, nije ispitana i stoga je treba izbjegavati.
Co-administration with atazanavir may cause a large increase in the concentration of these benzodiazepines.
Istovremena primjena atazanavira može jako povećati koncentracije ovih benzodiazepina.
g Select substitutions include any change at positions L10, K20, L24, V32, L33, M36, M46, G48, I50, I54, L63, A71,
g Odabrane supstitucije uključuju svaku promjenu na položajima: L10, K20, L24, V32, L33, M36, M46, G48, I50, I54, L63,
SEDATIVES Benzodiazepines Midazolam Triazolam
Midazolam Triazolam
Stevens-Johnson syndrome (SJS), erythema multiforme, toxic skin eruptions and drug rash with eosinophilia and systemic symptoms (DRESS) syndrome have been reported with the use of atazanavir (see section 4.4).
Stevens-Johnsonov sindrom (SJS), multiformni eritem, erupcija kožnih promjena uzrokovanih toksičnim učinkom lijeka i kožni osip uzrokovan lijekom s eozinofilijom i sistemskim simptomima (DRESS) zabilježeni su kod primjene atazanavira (vidjeti dio 4.4).
boceprevir AUC ↔5% boceprevir cmax ↔7% boceprevir cmin ↔18%
boceprevir Cmax ↔7% boceprevir Cmin ↔18%
Atazanavir Krka capsules, co-administered with low dose ritonavir, are indicated for the treatment of HIV-1 infected adults and paediatric patients 6 years of age and older in combination with other antiretroviral medicinal products (see section 4.2).
4.1 Terapijske indikacije Atazanavir Krka kapsule, koje se primjenjuju istovremeno s niskom dozom ritonavira, indicirane su u kombinaciji s drugim antiretrovirusnim lijekovima za liječenje odraslih i pedijatrijskih bolesnika u dobi od 6 godina i starijih, koji su zaraženi virusom HIV-1 (vidjeti dio 4.2).